A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Completed
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +139 locations
Conditions: Amyloidosis
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Completed
The purpose of Phase 1b of this study is to: * Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL). * Determine the maximum tolerated dose (MTD) and to recommend a phase 2 dose of carfilzomib in combination with induction chemotherapy. The purpose of Phase 2 of this study is to compare the rate of complete remission (CR) of carfilzomib in combination with vin... Read More
Gender:
ALL
Ages:
Between 1 month and 21 years
Trial Updated:
05/16/2025
Locations: University of California San Francisco Benioff Childrens Hospital Oakland, Oakland, California +121 locations
Conditions: Acute Lymphoblastic Leukemia (ALL)
Comparing Pain Relief Between Two Methods of Freezing Injections in Children Having Their Appendix Removed
Enrolling By Invitation
Laparoscopic appendectomies are the most common emergency surgeries performed in children. Despite being considered minimally invasive surgeries, they can result in substantial postoperative pain and 2 of 3 patients require postoperative opioids. Increased postoperative pain can delay recovery, increase hospital admission time, lead to chronic pain, and cause patient distress. This study aims to reduce postoperative pain in this population by comparing the recovery outcomes associated with the a... Read More
Gender:
ALL
Ages:
Between 4 years and 18 years
Trial Updated:
05/14/2025
Locations: British Columbia Children's Hospital, Vancouver, British Columbia
Conditions: Laparoscopic Appendectomy
Dexamethasone Treatment for OSA in Children
Active Not Recruiting
This is a double-blinded clinical trial of children diagnosed with moderate to severe obstructive sleep apnea (OSA) on a baseline polysomnogram (PSG). Participants will receive a 3-day course of dexamethasone, an oral steroid, or placebo control and undergo two PSGs to assess the efficacy of dexamethasone, as a treatment to manage the severity and symptoms in children with moderate to severe OSA.
Gender:
ALL
Ages:
Between 2 years and 10 years
Trial Updated:
05/13/2025
Locations: The Hospital for Sick Children, Toronto, Ontario
Conditions: Obstructive Sleep Apnea
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Recruiting
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
05/12/2025
Locations: BCCA - Vancouver, Vancouver, British Columbia +3 locations
Conditions: Lymphoma, B-Cell
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Recruiting
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Concord Repatriation General Hospital, Concord, New South Wales +16 locations
Conditions: Hodgkin Lymphoma
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Completed
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Lynn Cancer Center Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida +112 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Active Not Recruiting
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/30/2025
Locations: The Childrens Hospital of Alabama, Birmingham, Alabama +110 locations
Conditions: Leukemia
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Active Not Recruiting
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Carfilz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of California, San Francisco, San Francisco, California +5 locations
Conditions: Multiple Myeloma
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Completed
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Not set, Little Rock, Arkansas +145 locations
Conditions: Multiple Myeloma
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Terminated
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Arizona Oncology Associates , PC - HOPE, Tucson, Arizona +21 locations
Conditions: Multiple Myeloma
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Active Not Recruiting
The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
04/14/2025
Locations: Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta +12 locations
Conditions: Lymphoma